Repare Therapeutics Inc. — Director's Dealing 2020

Jun 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Repare Therapeutics Inc. (RPTX)
CIK: 0001808158
Period of Report: 2020-06-23

Reporting Person: GADICKE ANSBERT (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-23	Common Shares	C	3603161	—	Acquired	3603161	Indirect
2020-06-23	Common Shares	C	1288948	—	Acquired	4892109	Indirect
2020-06-23	Common Shares	P	500000	$20.00	Acquired	5392109	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-23	Class A Preferred Shares	$	C	3603161	Disposed		Common Shares (3603161)	Indirect
2020-06-23	Class B Preferred Shares	$	C	1288948	Disposed		Common Shares (1288948)	Indirect

Footnotes

F1: All series of convertible preferred shares converted into the number of shares of the Issuer's common shares on a 1-for-1 basis, for no additional consideration, immediately prior to the closing of the Issuer's initial public offering and had no expiration date.

F2: The shares are held as follows: 1,636,136 by MPM BioVentures 2014, L.P. ("BV 2014"), 109,128 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 56,317 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 1,801,580 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Ansbert Gadicke is a managing director of BV LLC and a member of AM BV2014. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC.

F3: The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

F4: The shares are held as follows: 2,500,885 by BV 2014, 166,805 by BV 2014(B), 86,082 by AM BV2014 and 2,138,337 by UBS Oncology.

F5: The shares were purchased as follows: 227,042 by BV 2014, 15,143 by BV 2014(B), 7,815 by AM BV2014 and 250,000 by UBS Oncology.

F6: The shares are held as follows: 2,727,927 by BV 2014, 181,948 by BV 2014(B), 93,897 by AM BV2014 and 2,388,337 by UBS Oncology.

F7: No securities held by the Reporting Person.